It soared to 13 in one day… The reason why Ildong Pharmaceutical’s share price collapsed is Han Jae-young’s bio hot and cold.

Among the domestic pharmaceutical and bio stocks, we select and look into the most ‘hot’ and ‘cold’ stocks for a week. <한재영의 바이오 핫앤드콜드>is published every Saturday.

Among pharmaceutical and bio stocks in the last week of December, Ildong Pharmaceutical received the most attention from investors.

Ildong Pharmaceutical fell 27.31% on the 28th, followed by a 4.67% drop on the 29th, the last trading day of this year.

The stock price of Ildong Pharmaceutical, which started trading last week at 41,200 won, fell to 28,550 won in an instant.

Most of the rise that soared to the upper limit on the 15th of last month, immediately following the Japanese Ministry of Health, Labor and Welfare announced that they were discussing whether to approve the emergency use of the Corona 19 treatment ‘Zokoba’, was returned.

Ildong Pharmaceutical’s stock price is on a roller coaster because of the edible Corona 19 treatment, Zocoba.

Zokoba is a COVID-19 treatment developed by Ildong Pharmaceutical and Japan’s Shionogi Pharmaceutical. Ildong Pharmaceutical has domestic sales rights.

The active ingredient in Zokoba is encitrelvir.

Like Pfizer’s COVID-19 treatment paxrovid (ritonavir narmatrelvir), it is an antiviral drug, as can be seen from the ending in ‘vir’.

It inhibits 3CL protease, a proteolytic enzyme used by the COVID-19 virus to replicate itself. As a result, it prevents the proliferation of SARS-CoV-2, the virus that causes COVID-19.

Domestic introduction was expected, but on the 28th, the Korea Centers for Disease Control and Prevention decided not to request emergency use approval for Jokoba. In Japan, it received emergency use approval on the 22nd of last month.

As a result, Ildong Pharmaceutical’s stock price soared 13% the next day.

The Agency for Disease Control and Prevention discussed the clinical effectiveness and safety of Zokova, and above all, the feasibility of emergency introduction in Korea, but judged that the need for emergency use approval was low.

The Agency for Disease Control and Prevention said, “We will continue to monitor the overseas emergency use approval, follow-up clinical results, and purchase and utilization.”

In a short period of time, it is unlikely that Zokoba will be supplied to Korea following obtaining approval from our quarantine authorities. The sharp drop in the stock price seems to be due to this effect.

However, domestic introduction has not completely failed.

Ildong Pharmaceutical is said to have been preparing for conditional permission in preparation for the possibility of emergency use approval being canceled. Obtaining approval first is a condition of submitting a clinical final report.

Celltrion’s COVID-19 antibody treatment Leckirona and SK Bioscience’s COVID-19 vaccine SkyCoby1 also received domestic approval on the condition that they submit a final clinical report.

In phase 2 and 3 clinical trials conducted in Japan and Korea, Zokova took 167.9 hours (median value) to improve symptoms, showing an improved effect compared to 192.2 hours of placebo.

The secondary evaluation index, viral ribonucleic acid (RNA) in the body, was also significantly reduced. Dosage: Take 1 tablet per day for a total of 5 days.

Reporter Han Jae-young [email protected]